Table 1 Baseline patient parameters

Age (years), median (IQR)

72.0 (61.5–77.5)

71.0 (59.0–77.0)

0.549

Sex (male/female)

46/15

54/17

0.931

Single chamber ICD, n (%)

27 (44.3)

29 (40.8)

0.291

Dual chamber ICD, n (%)

7 (11.5)

17 (23.9)

CRT-defibrillator, n (%)

18 (29.5)

22 (30.1)

0.854

CRT-pacemaker, n (%)

9 (14.6)

3 (4.2)

0.037

ICD for secondary prevention of SCD, n (%)

16 (26.2)

17 (23.9)

0.763

Implantation time before study inclusion months (mean ± SD)

26.5 ± 10.3

28.3 ± 12.4

0.831

Comorbidities:

Hypertension, n (%)

55 (90.2)

56 (78.9)

0.078

Diabetes, n (%)

30 (49.2)

34 (47.8)

0.235

Dyslipidaemia, n (%)

33 (54.1)

36 (50.7)

0.297

Atrial fibrillation, n (%)

24 (39.3)

22 (32.4)

0.410

NYHA class, n (%)

II: 16 (26.2)

II: 48 (66.2)

 < 0.001

III: 45 (73.8)

III: 23 (33.8)

Chronic kidney disease, n (%)

15 (24.6)

12 (16.9)

0.277

Chronic lung disease, n (%)

12 (19.7)

15 (21.1)

0.837

Ischemic heart disease, n (%)

39 (63.9)

43 (60.6)

0.692

Previous myocardial infarction, n (%)

33 (54.1)

18 (25.4)

0.001

Previous open heart surgery

18 (31.6)

21 (32.4)

0.922

LV systolic function/diameter:

LVEF, median (IQR)

35.0 (30.0–48.0)

38.0 (31.0–45.0)

0.073

LV EDD, median (IQR)

62.0 (54.00–65.0)

59.0 (56.0–68.5)

0.980

LV ESD, median (IQR)

45.0 (43.0–50.0)

45.5 (41.0–50.5)

0.852

Medications:

ACEi/ARB (%)

95.1

80.28

0.048

ARNI (%)

4.9

12.7

0.036

BB (%)

95.1

100.0

0.065

MRA (%)

59.0

59.1

0.32

Amiodarone (%)

34.4

36.8

0.201

Antiplatelet agent (%)

55.7

38.2

0.047

OAC (%)

44.3

47.1

0.751

Statin (%)

55.1

43.6

0.041